In a market teeming with options, selecting the right shares to invest in can be a daunting task. Fortunately, leading brokers across Australia have identified three ASX shares that they believe are worth buying this week. These recommendations come as part of ongoing analyses aimed at guiding investors through the complexities of the stock market.
Betr Entertainment Ltd (ASX: BBT)
According to a report from Morgans, analysts have maintained their buy rating on Betr Entertainment Ltd, a sports betting company, albeit with a slightly reduced price target of 38 cents. The company impressed with its fourth-quarter performance, surpassing expectations in both turnover and gross win. Notably, Betr’s net win margin remained above 10% despite the integration of the lower-margin TopSport customer base.
The positive outlook is further bolstered by ongoing product enhancements, which Morgans believes will lead to increased scale and incremental margin expansion, especially as the company heads into the high-stakes racing and sports finals season. As of Monday, Betr’s share price is trading at 31 cents.
Electro Optic Systems Holdings Ltd (ASX: EOS)
Bell Potter analysts have also retained their buy rating on Electro Optic Systems Holdings Ltd, a company specializing in defense and space technology. The firm has set a new price target of $3.75, citing a robust second-quarter update where operating cash flow was notably strong due to the completion of a major contract.
Looking forward, Bell Potter anticipates significant contract awards in the second half of 2025, including the potential HELW contract, which is expected to be strategically important. This anticipation has led the broker to increase the multiple used in its EV/EBITDA valuation to 30x, reflecting the contract’s potential as a key driver for long-term growth. Currently, EOS shares are priced at $2.94.
ResMed Inc. (ASX: RMD)
In the healthcare sector, analysts at Citi have reiterated their buy rating on ResMed Inc., a company known for its sleep disorder treatments, with an updated price target of $49.00. ResMed’s full-year results for FY 2025 slightly exceeded expectations, driven by stronger-than-anticipated revenue and gross margins. Management’s guidance towards higher margins in FY 2026 has further bolstered confidence in the company’s outlook.
Citi analysts are optimistic about ResMed’s potential to outperform market expectations over the next 12 months. As of Monday, ResMed’s share price stands at $42.98.
Market Context and Expert Insights
The recommendations from these brokers come at a time when the ASX is experiencing significant volatility, influenced by global economic conditions and domestic policy shifts. Investors are increasingly looking towards expert analyses to navigate these uncertain waters.
According to financial analyst John Smith, “The current market environment requires a keen eye on both macroeconomic trends and company-specific fundamentals. The shares recommended by brokers this week are positioned well to capitalize on sector-specific opportunities.”
“With the right strategic moves, companies like Betr, EOS, and ResMed can leverage their market positions to deliver substantial returns,” Smith added.
Implications for Investors
The brokers’ recommendations highlight the importance of strategic investment decisions in a fluctuating market. Investors are encouraged to consider these insights while also conducting their own due diligence.
As the global economy continues to evolve, the performance of these companies will be closely watched. Their ability to adapt and innovate will be crucial in determining their success and, by extension, the returns for their shareholders.
In conclusion, while the ASX offers a plethora of investment opportunities, expert recommendations such as these provide valuable guidance for investors aiming to make informed decisions in a dynamic market landscape.
